Novanta Inc. (NOVT) Stock Price & Analysis
Novanta Inc. (NOVT) closed at USD 140.8 on Friday, October 23, 2026, up 3.03% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 136.66; the Oct 23, 2026 session ranged USD 132.2–141.28 on volume of 392,803 shares. Market capitalization is $5.32B, with a 52-week range of USD 98.27–176.38 (NMS). Source: Nexqual, retrieved October 24, 2026 at 17:54 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NOVT.md
Key facts (NOVT)
- Last four reported quarters (through Jul 3, 2026): revenue $1.03B, net income $61.8M (6.0% margin), free cash flow $114M (SEC filings).
- Valuation: P/E 86.2x (avg 83.5x at the last 3 fiscal year-ends), EV/EBITDA 31.4x, net cash $489M.
- 2 of 80 tracked superinvestors hold NOVT (13F, Q2 2026): 2 new, 0 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $5.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 1.67 on a 1–5 scale) (3 analysts), mean target USD 194.5 (range 194–195).
- Total return with dividends: 1Y +9.4% vs S&P 500 +13.4%; 5Y -18.4% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD 0.97, revenue estimate $301M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NOVT)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $707M | $861M | $882M | $949M | $981M | $1.03B |
| Gross profit | $300M | $378M | $400M | $422M | $435M | — |
| Operating income | $64.1M | $103M | $110M | $111M | $94.0M | $92.3M |
| Net income | $50.3M | $74.1M | $72.9M | $64.1M | $53.8M | $61.8M |
| EPS (diluted) | $1.41 | $2.06 | $2.02 | $1.77 | $1.47 | — |
| Free cash flow | $74.6M | $71.1M | $100M | $141M | $48.4M | $114M |
| Gross margin | 42.5% | 44.0% | 45.4% | 44.4% | 44.4% | — |
| Operating margin | 9.1% | 12.0% | 12.5% | 11.6% | 9.6% | 9.0% |
| Net margin | 7.1% | 8.6% | 8.3% | 6.8% | 5.5% | 6.0% |
| Revenue growth | +19.7% | +21.8% | +2.4% | +7.7% | +3.3% | — |
| Cash + short-term investments | $117M | $100M | $105M | $114M | $381M | — |
| Total debt | $434M | $435M | $354M | $417M | $251M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jul 3, 2026) (NOVT)
P/E 86.2x · P/S 5.2x · EV/EBITDA 31.4x · EV/Sales 4.7x · P/FCF 46.6x · P/B 3.3x · FCF yield 2.15% · Earnings yield 1.16% · Buyback yield (TTM) 0.97% · Net cash $489M · EV $4.84B
P/E at fiscal year-ends: Dec 2025 81.1x, Dec 2024 86.1x, Dec 2023 83.3x.
Superinvestors (SEC 13F-HR, Q2 2026) (NOVT)
2 of 80 tracked investors hold NOVT. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Torray Funds | 0.24% | $1.8M | New position | |
| Polen Capital | Polen Capital Management | 0.02% | $2.2M | New position |
Insider sales (SEC Form 4, open-market, last ~7 months) (NOVT)
6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-11 | Secor Thomas N | Director | 663 | $98K | 50% | Yes (adopted June 12, 2026) | Too little history (no open-market trades in 2023) |
| 2026-07-02 | Glastra Matthijs | Chief Executive Officer | 6,500 | $1.0M | 7.2% | Yes (adopted September 11, 2025) | Too little history (no open-market trades in 2025) |
| 2026-06-02 | Glastra Matthijs | Chief Executive Officer | 6,500 | $1.1M | 6.7% | Yes (adopted September 11, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-12 | Glastra Matthijs | Chief Executive Officer | 7,500 | $1.1M | 7.2% | Yes (adopted September 11, 2025) | Too little history (no open-market trades in 2025) |
| 2026-05-05 | Glastra Matthijs | Chief Executive Officer | 6,500 | $852K | 5.8% | Yes (adopted September 11, 2025) | Too little history (no open-market trades in 2025) |
| 2026-04-17 | Glastra Matthijs | Chief Executive Officer | 6,500 | $845K | 5.5% | Yes (adopted September 11, 2025) | Too little history (no open-market trades in 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NOVT)
Consensus Buy (mean 1.67 on a 1–5 scale), 3 analysts; mean target USD 194.5 (low 194, high 195).
Total return (dividends reinvested) (NOVT)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +9.4% | -18.4% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +9.5% | -4.0% |
| Volatility (annualized) | 52.3% | 41.4% |
| Max drawdown | -27.0% (Nov 2025→Nov 2025) | -46.0% (Jul 2024→Oct 2025) |
NOVT revenue by business segment (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Automation Enabling Technologies | $136.2M | 51.2% | +12.0% |
| Medical Solutions | $129.6M | 48.8% | +8.6% |
| Total revenue | $265.8M | 100% | — |
NOVT revenue by product line (quarter ended Sep 26, 2025)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Robotics & Automation | $80.1M | 32.3% | +0.1% |
| Advanced Surgery | $61.7M | 24.9% | +17.2% |
| Precision Medicine | $60.8M | 24.6% | -3.6% |
| Precision Manufacturing | $45.2M | 18.2% | -7.2% |
| Total revenue | $247.8M | 100% | — |
NOVT revenue by region (quarter ended Jul 3, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $131.4M | 49.4% | +2.6% |
| Rest Of Europe | $38.1M | 14.3% | +9.3% |
| Germany | $33.3M | 12.5% | +22.2% |
| Rest Of Asia Pacific | $28.5M | 10.7% | +15.4% |
| China | $25.5M | 9.6% | +16.9% |
| Other Countries | $9.1M | 3.4% | +106.8% |
| Total revenue | $265.8M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
NOVT customer concentration
In the period ended Dec 31, 2025, 2 direct customers each accounted for at least 10% (12%, 11%) of revenue, per the company's 10-K filed Feb 23, 2026. The company does not name them.
NOVT company outlook (results filed Aug 5, 2026)
- “Financial Guidance "As we enter the second half of 2026, we are encouraged by the accelerating momentum across our portfolio.”
- “We expect Riverpoint to be immediately accretive to revenue growth, gross margins, EBITDA margins, and earnings per share." For the third quarter of 2026, the Company expects GAAP revenue to be in the range of $300 million to $304 million, or greater than 21% revenue growth.”
- “The Company expects Adjusted EBITDA to be in the range of $74 million to $77 million and Adjusted Diluted EPS to be in the range of $0.95 to $1.00 per diluted share.”
- “The Company's guidance now incorporates the expected contribution from the Riverpoint Medical acquisition and assumes no significant changes in foreign exchange rates.”
Analysts expect $301.0M for the current quarter, 0.3% below the midpoint of the company's guidance ($302.0M).
Quoted word-for-word from the SEC 8-K results press release.
NOVT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.97 | $0.94 | +2.8% | $301.0M | 3 |
| Next quarter (ends Dec 2026) | $1.02 | $1.00 | +2.0% | $308.8M | 3 |
| Current fiscal year (ends Dec 2026) | $3.69 | $3.59 | +2.9% | $1.13B | 3 |
| Next fiscal year (ends Dec 2027) | $4.37 | $4.14 | +5.4% | $1.31B | 3 |
NOVT options: expected move
Options price a move of about ±12.9% (±$18.15) by Nov 20, 2026, which includes earnings on Nov 9, 2026. Over the last 8 reports the stock moved ±5.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 27 | 58.6% | ±12.9% |
| Dec 18, 2026 | 55 | 53.9% | ±16.7% |
| Feb 19, 2027 | 118 | 49.4% | ±22.3% |
| Mar 19, 2027 | 146 | 51.1% | ±25.6% |
| May 21, 2027 | 209 | 51.5% | ±30.7% |
| Sep 17, 2027 | 328 | 51.4% | ±38.2% |
30-day implied volatility 58.8% vs 48.1% realized over the last 30 trading days. Put/call ratio (volume) 12.5. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 24, 2026 at 17:54 UTC)
| Price | USD 140.8 |
|---|---|
| Change | ▲ 3.03% (up) |
| Previous Close | USD 136.66 |
| Open | USD 135.22 |
| Day Range | USD 132.2 – 141.28 |
| 52-Week Range | USD 98.27 – 176.38 |
| Volume | 392,803 shares |
| Market Cap | $5.32B |
| Exchange | NMS |
Technical Analysis (NOVT)
Nexqual's technical model rates NOVT "SELL" based on 1 bullish and 4 bearish signals across 127 daily candles, as of October 24, 2026 at 17:54 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 48.93 (neutral) |
| vs SMA50 | Below (USD 143.18) |
| MACD | -1.86 (negative) |
Analyst Ratings (NOVT)
Wall Street analysts rate NOVT "Buy" based on 3 analysts, with a mean price target of USD 194.5 (range USD 194–195), per Nexqual as of October 24, 2026 at 17:54 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 194.5 |
| High Target | USD 195 |
| Low Target | USD 194 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NOVT)
| Next Earnings Date | 2026-11-09 |
|---|---|
| EPS Estimate | USD 0.97 |
| Revenue Estimate | $301.02M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.89 vs est 0.83 ▲ beat |
| 2026-03-31 | USD 0.81 vs est 0.78 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.88 ▲ beat |
| 2025-09-30 | USD 0.87 vs est 0.82 ▲ beat |
Source: Nexqual, October 24, 2026 at 17:54 UTC.
Financials & Fundamentals (NOVT)
| Total Revenue | $1.03B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.30% |
| Gross Margin | +44.54% |
| Operating Margin | +11.50% |
| Profit Margin | +6.00% |
| ROE | +5.11% |
| Debt / Equity | 0.18 |
| Current Ratio | 4.57 |
| Total Cash | $718.65M |
| Total Debt | $285.60M |
| Free Cash Flow (last four quarters to Jul 2026, SEC 10-Q / 10-K) | $114.28M (11.1% of revenue) |
Source: Nexqual, October 24, 2026 at 17:54 UTC.
Financial Health Score (NOVT)
Nexqual rates Novanta Inc.'s overall financial health "Solid" across five dimensions, as of October 24, 2026 at 17:54 UTC.
| Growth | Mixed — Revenue +3.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 45%, operating 11% (last 12 months) |
| Balance Sheet | Strong — $719M cash and investments vs $230M debt (Jul 2026, SEC), net cash |
| Cash Flow | Solid — FCF $114M (last 4 quarters to Jul 2026, SEC), 11% margin |
| Efficiency | Mixed — ROE 5%, ROA 4.1% |
Ownership (NOVT)
| Insider Ownership | +0.71% |
|---|---|
| Institutional Ownership | +124.07% |
| Shares Outstanding | 37.82M |
| Float | 37.54M |
| Short % of Float | +15.64% |
Source: Nexqual, October 24, 2026 at 17:54 UTC.
Leadership (NOVT)
Novanta Inc. is led by Matthijs Glastra, CEO & Chairman of the Board, per Nexqual as of October 24, 2026 at 17:54 UTC.
| CEO & Chairman of the Board | Matthijs Glastra |
|---|---|
| Chief Financial Officer | Robert J. Buckley |
| Co-Chief Operating Officer of Automation Enabling Technologies | Charles G. Ravetto |
| Co-Chief Operating Officer of Medical Solutions | John Lesica |
| Senior Vice President of Corporate Development | Nissia Sabri |
Major Backers & Investors (NOVT)
Notable institutional backers of Novanta Inc. include Price (T.Rowe) Associates Inc, Allspring Global Investments Holdings, LLC, Conestoga Capital Advisors, LLC, according to Nexqual as of October 24, 2026 at 17:54 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 5.88% |
| Allspring Global Investments Holdings, LLC | 4.81% |
| Conestoga Capital Advisors, LLC | 3.22% |
| Wasatch Advisors LP | 2.78% |
| Congress Asset Management Co | 2.59% |
| T. Rowe Price | 2.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.69% |
| Vanguard Group | 10.58% |
| State Street | 3.8% |
| Geode Capital | 2.61% |
Source: Nexqual, October 24, 2026 at 17:54 UTC.
From Novanta Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA's General Controls for medical devices, which include compliance with the applicable portions of the Quality Management System Regulation (the "QMSR"), facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials.
- We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges.
- We also protect our proprietary rights by controlling access to our proprietary information and by maintaining confidentiality agreements with our employees, consultants, and certain customers and suppliers.
Legal & Regulatory Risks (Item 1A, quoted)
- We produce complex products that can contain latent defects or performance problems. This could happen to both existing and new products. Such defects or performance problems could result in litigation against us and be detrimental to our business and reputation.
- We are subject to extensive and dynamic medical device regulations, which may impede or hinder the approval, certification or sale of our products and, in some cases, may ultimately result in an inability to obtain approval or certification of certain products or may result in the recall or seizure of previously approved or certified products.
- Our products and operations are subject to various foreign and U.S. federal and state healthcare laws and regulations, which could expose us to penalties.
- Changes in government regulations related to our business or our products could reduce demand for our products or increase our expenses.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ST | Sensata Technologies Holding pl | USD 40.38 | ▼ 0.79% |
| ESE | ESCO Technologies Inc. | USD 232.1 | ▼ 0.38% |
| VNT | Vontier Corporation | USD 34.36 | ▼ 0.52% |
| BMI | Badger Meter, Inc. | USD 151.24 | ▲ 1.07% |
| ITRI | Itron, Inc. | USD 87.65 | ▼ 0.59% |
| CGNX | Cognex Corporation | USD 55.55 | ▲ 1.74% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 17:54 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt